Tucidinostat (Chidamide)

For research use only. Not for use in humans.

目录号:S8567 别名: HBI-8000, CS-055

Tucidinostat (Chidamide) Chemical Structure

CAS No. 1616493-44-7

Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩尔浓度抑制剂,IC50分别为95、160、67、78 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 794.43 现货
RMB 795.33 现货
RMB 2023.28 现货
RMB 5299.86 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Tucidinostat (Chidamide)发表文献9篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩尔浓度抑制剂,IC50分别为95、160、67、78 nM。
靶点
HDAC3 [1]
(Cell-free)
HDAC10 [1]
(Cell-free)
HDAC1 [1]
(Cell-free)
HDAC2 [1]
(Cell-free)
67 nM 78 nM 95 nM 160 nM
体外研究

Chidamide抑制I型HDACs 1-3,以及IIb型HDAC10。在人类宫颈腺癌Hela细胞和人源PBMC细胞中,Chidamide显著地诱导组蛋白H3乙酰化。在微摩尔浓度范围内,Chidamide和MS-275可抑制大多数人源肿瘤细胞系的细胞生长,但并不是所有所检测的肿瘤细胞(共检测18种)。在人胚肾(CCC-HEK)和人胚肝(CCC-HEL)中,Chidamide对正常细胞的毒性作用比MS-275大大减少,说明Chidamide对正常细胞和癌细胞的细胞毒性作用的差异[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 NFTRRXBHfW6ldHnvckBie3OjeR?= NXfPdlI6PSCvaX7z MkD6TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDibY91cW67bHH0[YQhdHm|aX7lJFkh[WOndInsZZRm\CCqaYP0c45mKEh|IDixJJRwKDJzIILld4llfWW|KTDhd{B{fWK|dILheIUhcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IE[wJI1qNCCLQ{WwJF0hOC5zMUKg{txONg>? M33X[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO1O|k4Lz5{OEizOVc6PzxxYU6=
EBC1 NEXBOZBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NIK1VFE4OiCqcoO= NUXlUZNKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCyMlkh|ryPLh?= NGPweYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pyd-Mki4N|U4QTd:L3G+
HCT116 NGjQZpRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFnGO2Y4OiCqcoO= MmjURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEeuPEDPxE1w MlH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W3PVcoRjJ6OEO1O|k4RC:jPh?=
HL60 NF\zNVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\sOFghcHK| NF7uS2pIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJVDZyIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUAxNjRizszNMi=> NHPwe5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
Jurkat M{Tnc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVfQdnFSPDhiaILz M4XEO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGp2emujdDDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hOS53IN88UU4> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
hematopoietic malignant cells MVPDfZRwfG:6aXPpeJkh[XO|YYm= M371dmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIhmdWG2b4DvbYV1cWNibXHsbYdv[W62IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wLDDHTVUxKD1iMT64OkDPxE1w MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHO0[no1QCCqcoO= NEHzdYpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBWOk:VIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUAzKM7:TT6= NEHVW5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
HepG2 MkL6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\YO|Q5KGi{cx?= M17MbWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmeEd{IHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUA1KM7:TT6= MmjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
LNCAP NGLCcWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY\uSVZ3PDhiaILz MWLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDMUmNCWCClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gOEDPxE1w MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
Raji M1vuTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHlV4N7PDhiaILz M3\LSGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHJicmliY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFQh|ryPLh?= MmPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
MCF7 MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGn3RWc1QCCqcoO= MWjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNR2Y4KGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UV{Bu\XSqb3SsJGdKPTBiPTC1JO69VS5? MnHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
28SC MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV[0PEBpenN? MmXES5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gNlhUSyClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gOU45KM7:TT6= NWL5bJpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
PANC1 NUH4T4FzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDWZ2FzPDhiaILz Ml\RS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGFPSzFiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFYvOyEQvF2u Mlf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
human solid tumor cells NHXEb4xEgXSxdH;4bYNqfHliYYPzZZk> M1fMO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJNwdGmmIIT1cY9zKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vNCCJSUWwJF0hPi54NTFOwG0v MlPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
HeLa NV7XTHBoTnWwY4Tpc44h[XO|YYm= NWDv[GdjOTBibXnudy=> NUTUe40xUW6qaXLpeIlwdiCxZjDISGFEKGWweontZZRq[yCjY4Tpeol1gSCrbjDoeY1idiCKZVzhJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOTBibXnud{BqdiCycnXz[Y5k\SCxZjDzeYJ{fHKjdHWgZpkh[2:ub4LpcYV1emmlIHHjeIl3cXS7IHHzd4F6NCCLQ{WwJF0hPy5{IN88UU4> Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
MDA-MB-231 M3n2bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVS0PEBpenN? NWHJd|R6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gO{46KM7:TT6= NIT0SWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
SMMC7721 M3XOdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2K4flQ5KGi{cx?= MorCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV21OSzd5MkGgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSVIH3leIhw\CxiR1m1NEA:KDF4IN88UU4> M1Ttd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
DU145 M3XmWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUm0PEBpenN? NEPsW4RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hOjVizszNMi=> M2niNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
HeLa NXTZU29WT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUf2c|BEPDhiaILz NWC5bFJIT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWOYTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hPDBizszNMi=> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS NG\1XIFHfW6ldHnvckBie3OjeR?= M3nmXFEhfU1? MnS1NlQhcHK| M3;vWWFkfGm4YYTpc44hd2ZiUGDBVmchMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwIIDy[ZNmdmOnIH;mJFExKHWPIILvd4lodGm2YYrvcoUhcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NEToV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS NWm5dGV{TnWwY4Tpc44h[XO|YYm= M3z2RVEhfU1? M4DDRVI1KGi{cx?= M2K4SmFkfGm4YYTpc44hd2ZiRWLi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbjDwdoV{\W6lZTDv[kAxNjBzIIXNJGUzKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NIKxS5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS MVXGeY5kfGmxbjDhd5NigQ>? MlXDNUB2VQ>? MnXjNlQhcHK| M3PtV2FkfGm4YYTpc44hd2ZiZ3z1cINw[2:{dHnjc4llKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbjDwdoV{\W6lZTDv[kAxNjFidV2g[IV5[W2ndHjhd49v\SCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS MYnGeY5kfGmxbjDhd5NigQ>? MUCxJJVO MVKyOEBpenN? NGfO[|dC[3SrdnH0bY9vKG:oIFXSZYxxcGFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iVULPV{Bk\WyuczDheEAyKHWPIHnuJJBz\XOnbnPlJI9nKDBwMEGgeW0hTTJiaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7 MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS M{P4fGZ2dmO2aX;uJIF{e2G7 NGC2WmQyKHWP NUjIbnJPOjRiaILz MVjBZ5RqfmG2aX;uJI9nKGeudXzjc4NwenSrY3;p[EBz\WOncITvdkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCqdX3hckBWOk:VIHPlcIx{KGG2IEGgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS Mnj1SpVv[3Srb36gZZN{[Xl? MnizNUB2VQ>? MXSyOEBpenN? M4HpWGFkfGm4YYTpc44hd2ZiUGDBVmchMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? M{KzT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
U2OS NFO5e3ZHfW6ldHnvckBie3OjeR?= MXyxJJVO MlrnNlQhcHK| MnTPRYN1cX[jdHnvckBw\iCHUnHsdIhiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? NGPEcWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS NIjleIFHfW6ldHnvckBie3OjeR?= NHe4Vm8yKHWP Mk[2NlQhcHK| MkjLRYN1cX[jdHnvckBw\iCHUnLleIEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 30854137     


Expression and activation level of Caspase-3 and PARP after treatment of serial dilutions of chidamide in HCC827 cells (48h).

p-EGFR / EGFR / p-STAT3 / STAT3 / p-AKT / AKT / p-AMPK / MAPK ; 

PubMed: 30854137     


Chidamide inhibition of PTK signaling molecules in A549 cells (48h).

Ace-H3K18 / Ace-H3K9 / Ac-H4K8 ; 

PubMed: 29773595     


Western blot analysis of H3 acetylation at Lys18 and Lys9 and H4 acetylation at Lys8. H3 and H4 expression levels were used as loading controls. 

Mcl-1 / Myc / Bcl-xl / p21 / p27 / CDK6 / CDK4 / Cyclin D2 ; 

PubMed: 29773595     


Western blot analysis of Mcl-1, Myc, Bcl-xL, Bcl-2, p21, p27, CDK4, CDK6, and Cyclin-D2 levels; α-tubulin was used as the loading control. 

HDAC1 / HDAC2 / HDAC3 / acetyl-H3 / acetyl-H4 ; 

PubMed: 31289512     


(A) RPMI8226 cells were treated with 0, 0.5, 1 or 2 µmol/l chidamide for 48 h and (B) U266 cells were treated with 0, 2, 4 or 8 µmol/l chidamide for 48 h, and HDACs expression was assessed using western blot analysis.

30854137 29773595 31289512
Growth inhibition assay
Cell viability; 

PubMed: 29100410     


(a) Proliferation rates at 24, 48, 72 hour of Hs445 cells after treated with 0.1μM, 0.3μM, 1μM, 3μM, 10μM, 30μM Chidamides; (b) proliferation rates at 24, 48, 72 hours of L428 cells after treated with 0.1μM, 0.3μM, 1μM, 3μM, 10μM, 30μM Chidamide;

29100410
体内研究 在小鼠结肠癌HCT-8移植瘤模型中,Chidamide具有体内抗肿瘤活性。给药浓度范围为12.5-50 mg/kg的Chidamide可浓度依赖性地减少肿瘤大小和重量。Chidamide的给药浓度为50 mg/kg时,相较于对照药物组5-FU(20 mg/kg)和MS-275组(25 mg/kg)具有相似甚至更大的功效。在携瘤动物模型中,Chidamide耐受良好[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: PBMC效应细胞
  • Concentrations: 0-400 nM
  • Incubation Time: 24-72 h
  • Method:

    将分离的PBMC效应细胞接种于6孔板(细胞密度为6 x 106 cells/孔),用不同浓度的chidamide(0-400 nM)处理细胞一定时间(24-72 h)。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: Athymic nude mice (BALB/c-nu)
  • Dosages: 12.5-50 mg/kg
  • Administration: oral
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 78 mg/mL (199.78 mM)
Ethanol 2 mg/mL (5.12 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
1% CMC Na
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 390.41
化学式

C22H19FN4O2

CAS号 1616493-44-7
储存条件 粉状
溶于溶剂
别名 HBI-8000, CS-055

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04994210 Not yet recruiting Drug: Sintilimab|Drug: Chidamide Safety and Efficacy Sun Yat-sen University September 1 2021 Phase 2
NCT04651127 Recruiting Drug: Toripalimab + Chidamide Cervical Cancer|Cervix Cancer|Cervix Neoplasm Sun Yat-sen University November 9 2020 Phase 1|Phase 2
NCT03820596 Recruiting Drug: Sintilimab|Drug: Chidamide Safety and Efficacy Huiqiang Huang|Sun Yat-sen University March 29 2019 Phase 1|Phase 2
NCT02944812 Unknown status Drug: Chidamide Peripheral T Cell Lymphoma Guangdong Provincial People''s Hospital March 2016 Phase 2
NCT02569489 Withdrawn Drug: HBI-8000|Drug: Trastuzumab|Drug: Paclitaxel Breast Cancer HUYA Bioscience International December 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

相关HDAC产品

Tags: 购买Tucidinostat (Chidamide) | Tucidinostat (Chidamide)供应商 | 采购Tucidinostat (Chidamide) | Tucidinostat (Chidamide)价格 | Tucidinostat (Chidamide)生产 | 订购Tucidinostat (Chidamide) | Tucidinostat (Chidamide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID